GLP-1 drugs are much more than just weight loss
Recent work using fluorescence to monitor the LPL/GPIHBP1 complex has shown that LPL dissociates from GPIHBP1 in the presence of its substrate, chylomicrons, but also when excess product, free fatty acids (FFA), are added 66
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis, Endocrine Practice, Volume 30, Issue 2, 2024, Khan SS, Ndumele CE, Kazi DS
A study shows that when used with lifestyle changes, the weekly 2.4 mg dose of semaglutide reduced 10-15% of body weight compared to the placebo, which reduced body weight by only 2-3%
16%) and family coverage (31% vs